2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 118

Experiences and Perceptions of Patients with Rheumatoid Arthritis Participating in an Online Support Group: The Use of Social Media
Abstract Number: 119

Occupational Exposure to Asbestos and Risk of Rheumatoid Arthritis
Abstract Number: 120

Patients with Rheumatoid Arthritis Have Higher Lifetime Professional and Non-Professional Exposure to Silica Dust Particles Compared to General Population
Abstract Number: 121

Depression As a Risk Factor for the Development of Rheumatoid Arthritis: A Population-Based Cohort Study
Abstract Number: 122

Poor Prognostic Factors at the Start of Methotrexate Therapy Are Not Associated with Worse Treatment Response: Results from the Rheumatoid Arthritis Medication Study
Abstract Number: 123

Relationship between Shift Work and the Onset of Rheumatoid Arthritis; Results from a Swedish Case-Control Study
Abstract Number: 124

Smoking and Rheumatoid Arthritis Susceptibility; Quantification of the Impact of Cumulative Dose, Frequency and Duration of Smoking, and Smoking Cessation
Abstract Number: 125

Exposure to Passive Smoking and RA Risk; Results from a Swedish Case-Control Study
Abstract Number: 126

Smoking Is Causally Associated with Disease Activity in Rheumatoid Arthritis
Abstract Number: 127

Diet Change and Omega-3 Supplementation in the First Three Years Following a Diagnosis with Rheumatoid Arthritis in Sweden
Abstract Number: 128

Use of Machine Learning and Traditional Statistical Methods to Classify RA-Related Disability Using Administrative Claims Data
Abstract Number: 129

Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients
Abstract Number: 130

Availability of Clinical Measures for Patients with Rheumatoid Arthritis in Integrated Delivery Networks Who Receive a Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug: A Real-World Analysis of an Electronic Health Records Database
Abstract Number: 131

What Does It Mean to Have Rheumatoid Arthritis Now? a Current Burden of Disease Assessment in the United States
Abstract Number: 132

Occupational Physical Workload and Development of Anti-Collagen Type II Antibodies in Rheumatoid Arthritis Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].